United Therapeutics (UTHR) Stock Forecast, Price Target & Predictions
UTHR Stock Forecast
United Therapeutics stock forecast is as follows: an average price target of $458.00 (represents a 22.87% upside from UTHR’s last price of $372.75) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
UTHR Price Target
The average price target for United Therapeutics (UTHR) is $458.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $575.00 to $400.00. This represents a potential 22.87% upside from UTHR's last price of $372.75.
UTHR Analyst Ratings
According to 8 Wall Street analysts, United Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for UTHR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
United Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Jasper Hellweg | Argus Research | $400.00 | $362.36 | 10.39% | 7.31% |
| Oct 31, 2024 | Andrew Fein | H.C. Wainwright | $425.00 | $361.40 | 17.60% | 14.02% |
| Sep 23, 2024 | Eun Yang | Jefferies | $432.00 | $353.00 | 22.38% | 15.90% |
| Aug 28, 2024 | Hartaj Singh | Oppenheimer | $575.00 | $362.44 | 58.64% | 54.26% |
| Jul 08, 2024 | Ashwani Verma | UBS | $370.00 | $317.18 | 16.65% | -0.74% |
| Jun 12, 2024 | Tiago Fauth | Wells Fargo | $350.00 | $275.76 | 26.92% | -6.10% |
| May 02, 2024 | Hartaj Singh | Oppenheimer | $400.00 | $255.14 | 56.78% | 7.31% |
| Feb 12, 2024 | Chris Shibutani | Goldman Sachs | $215.00 | $214.74 | 0.12% | -42.32% |
| Jan 11, 2023 | Argus Research | $300.00 | $263.41 | 13.89% | -19.52% | |
| Dec 06, 2022 | Morgan Stanley | $330.00 | $276.07 | 19.53% | -11.47% | |
| Dec 06, 2022 | UBS | $320.00 | $273.72 | 16.91% | -14.15% | |
| Dec 05, 2022 | Goldman Sachs | $230.00 | $278.55 | -17.43% | -38.30% | |
| May 24, 2022 | J.P. Morgan | $238.00 | $218.00 | 9.17% | -36.15% | |
| May 24, 2022 | Jefferies | $245.00 | $217.13 | 12.83% | -34.27% | |
| May 24, 2022 | Credit Suisse | $247.00 | $210.14 | 17.54% | -33.74% | |
| May 24, 2022 | H.C. Wainwright | $255.00 | $210.14 | 21.35% | -31.59% | |
| Apr 19, 2022 | J.P. Morgan | $223.00 | $184.24 | 21.04% | -40.17% | |
| May 05, 2021 | Tiago Fauth | Credit Suisse | $205.00 | $198.14 | 3.46% | -45.00% |
The latest United Therapeutics stock forecast, released on Oct 31, 2024 by Jasper Hellweg from Argus Research, set a price target of $400.00, which represents a 10.39% increase from the stock price at the time of the forecast ($362.36), and a 7.31% increase from UTHR last price ($372.75).
United Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 8 |
| Avg Price Target | - | $412.50 | $395.88 |
| Last Closing Price | $372.75 | $372.75 | $372.75 |
| Upside/Downside | -100.00% | 10.66% | 6.21% |
In the current month, the average price target of United Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to United Therapeutics's last price of $372.75. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 08, 2025 | UBS | Buy | Buy | Hold |
| Oct 31, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 21, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Oct 21, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 23, 2024 | UBS | Underperform | Underperform | Hold |
| Sep 23, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 23, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 28, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 20, 2024 | UBS | Underperform | Underperform | Hold |
| Aug 20, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 20, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jul 25, 2024 | UBS | Underperform | Underperform | Hold |
| Jul 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 11, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 11, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Jul 08, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jul 08, 2024 | UBS | Buy | Buy | Hold |
| Jun 27, 2024 | Bank of America Securities | Underperform | Underperform | Hold |
| Jun 12, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jun 12, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Jun 12, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 02, 2024 | Wedbush | Underperform | Underperform | Hold |
| May 02, 2024 | Wells Fargo | Buy | Buy | Hold |
| May 02, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Feb 22, 2024 | Wedbush | Buy | Buy | Hold |
| Feb 22, 2024 | Leerink Partners | Underperform | Underperform | Hold |
| Feb 12, 2024 | Goldman Sachs | Sell | Neutral | Upgrade |
| Dec 06, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Dec 06, 2022 | UBS | Buy | Initialise | |
| Dec 05, 2022 | Goldman Sachs | Sell | Initialise | |
| May 24, 2022 | Jefferies | Buy | Buy | Hold |
| May 24, 2022 | Credit Suisse | Positive | Positive | Hold |
| May 24, 2022 | Cowen & Co. | Outperform | Outperform | Hold |
| May 24, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Feb 28, 2022 | Wedbush | Outperform | Outperform | Hold |
United Therapeutics's last stock rating was published by UBS on Jan 08, 2025. The company gave UTHR a "Buy" rating, the same as its previous rate.
United Therapeutics Financial Forecast
United Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $609.40M | - | $506.90M | $491.50M | $516.00M | $466.90M | $461.90M | $415.20M | $444.70M | $446.50M | $379.10M | $384.60M | $380.10M | $362.00M | $356.30M | $311.10M | $401.50M |
| Avg Forecast | $866.31M | $900.64M | $840.82M | $806.64M | $831.79M | $830.03M | $800.13M | $757.63M | $739.92M | $722.62M | $691.87M | $620.31M | $575.01M | $585.82M | $524.18M | $514.37M | $519.21M | $493.21M | $461.06M | $420.06M | $427.59M | $421.45M | $378.56M | $368.95M | $362.04M | $358.46M | $339.98M | $344.33M | $357.77M | $337.60M |
| High Forecast | $890.21M | $925.48M | $864.01M | $828.89M | $854.73M | $852.93M | $822.20M | $769.52M | $807.97M | $724.84M | $691.87M | $620.31M | $610.36M | $603.74M | $538.63M | $528.56M | $541.73M | $493.21M | $461.06M | $420.06M | $427.59M | $421.45M | $378.56M | $368.95M | $362.04M | $358.46M | $339.98M | $344.33M | $357.77M | $337.60M |
| Low Forecast | $845.87M | $879.39M | $820.98M | $787.61M | $812.17M | $810.45M | $781.26M | $745.74M | $693.93M | $720.39M | $691.87M | $620.31M | $538.02M | $561.00M | $511.81M | $502.24M | $497.77M | $493.21M | $461.06M | $420.06M | $427.59M | $421.45M | $378.56M | $368.95M | $362.04M | $358.46M | $339.98M | $344.33M | $357.77M | $337.60M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 9 | 4 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | - | 0.99% | 0.95% | 1.05% | 1.01% | 1.10% | 0.97% | 1.06% | 1.18% | 1.03% | 1.06% | 1.06% | 1.06% | 1.03% | 0.87% | 1.19% |
United Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $575.01M, with a low forecast of $538.02M, and a high forecast of $610.36M. UTHR's average Quarter revenue forecast represents a -5.64% decrease compared to the company's last Quarter revenue of $609.40M (Sep 23).
United Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 9 | 4 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $327.00M | - | $319.00M | $191.10M | $334.60M | $169.50M | $327.60M | $157.80M | $221.40M | $233.60M | $49.60M | $-117.50M | $235.70M | $152.10M | $192.20M | $90.80M | $191.30M |
| Avg Forecast | $338.60M | $352.02M | $328.63M | $315.28M | $325.11M | $324.42M | $312.73M | $296.12M | $289.20M | $282.44M | $270.42M | $106.50M | $224.74M | $228.97M | $204.87M | $96.82M | $237.51M | $181.35M | $169.53M | $88.02M | $157.22M | $154.96M | $139.19M | $80.02M | $133.12M | $131.80M | $125.01M | $166.34M | $131.55M | $124.13M |
| High Forecast | $347.94M | $361.73M | $337.70M | $323.97M | $334.07M | $333.37M | $321.36M | $300.77M | $315.80M | $283.31M | $270.42M | $127.80M | $238.56M | $235.97M | $210.53M | $116.19M | $285.01M | $181.35M | $169.53M | $105.62M | $157.22M | $154.96M | $139.19M | $96.02M | $133.12M | $131.80M | $125.01M | $199.61M | $131.55M | $124.13M |
| Low Forecast | $330.61M | $343.71M | $320.88M | $307.84M | $317.44M | $316.77M | $305.36M | $291.47M | $271.22M | $281.57M | $270.42M | $85.20M | $210.28M | $219.27M | $200.04M | $77.46M | $190.00M | $181.35M | $169.53M | $70.42M | $157.22M | $154.96M | $139.19M | $64.01M | $133.12M | $131.80M | $125.01M | $133.07M | $131.55M | $124.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.43% | - | 3.29% | 0.80% | 1.85% | 1.00% | 3.72% | 1.00% | 1.43% | 1.68% | 0.62% | -0.88% | 1.79% | 1.22% | 1.16% | 0.69% | 1.54% |
8 analysts predict UTHR's average Quarter EBITDA for Dec 23 to be $224.74M, with a high of $238.56M and a low of $210.28M. This is -31.27% lower than United Therapeutics's previous annual EBITDA (Sep 23) of $327.00M.
United Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 9 | 4 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $267.60M | - | $240.90M | $132.10M | $239.30M | $116.00M | $239.90M | $112.20M | $162.70M | $172.60M | $28.30M | $98.00M | $171.20M | $107.10M | $137.70M | $52.60M | $132.40M |
| Avg Forecast | $370.62M | $385.28M | $359.96M | $345.53M | $370.82M | $392.22M | $378.13M | $348.03M | $318.63M | $315.73M | $314.86M | $60.77M | $202.66M | $246.93M | $221.14M | $55.24M | $168.87M | $185.70M | $208.49M | $50.22M | $170.05M | $170.64M | $143.45M | $45.66M | $140.18M | $134.96M | $131.71M | $119.17M | $125.45M | $120.65M |
| High Forecast | $383.91M | $399.09M | $372.87M | $357.92M | $384.12M | $406.29M | $391.69M | $352.10M | $391.12M | $315.82M | $315.36M | $72.92M | $256.43M | $275.61M | $229.07M | $66.29M | $202.65M | $185.70M | $208.49M | $60.27M | $170.05M | $170.64M | $143.45M | $54.79M | $140.18M | $134.96M | $131.71M | $143.01M | $125.45M | $120.65M |
| Low Forecast | $359.26M | $373.46M | $348.92M | $334.93M | $359.45M | $380.20M | $366.53M | $343.46M | $253.19M | $315.64M | $314.37M | $48.61M | $153.55M | $194.92M | $214.36M | $44.19M | $135.10M | $185.70M | $208.49M | $40.18M | $170.05M | $170.64M | $143.45M | $36.52M | $140.18M | $134.96M | $131.71M | $95.34M | $125.45M | $120.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | - | 4.36% | 0.78% | 1.29% | 0.56% | 4.78% | 0.66% | 0.95% | 1.20% | 0.62% | 0.70% | 1.27% | 0.81% | 1.16% | 0.42% | 1.10% |
United Therapeutics's average Quarter net income forecast for Dec 23 is $202.66M, with a range of $153.55M to $256.43M. UTHR's average Quarter net income forecast represents a -24.27% decrease compared to the company's last Quarter net income of $267.60M (Sep 23).
United Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 9 | 4 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $127.60M | - | $87.30M | $166.10M | $98.40M | $141.50M | $79.00M | $127.90M | $109.10M | $112.80M | $117.20M | $103.80M | $66.30M | $105.90M | $93.00M | $105.20M | $99.40M |
| Avg Forecast | $216.82M | $225.41M | $210.44M | $201.89M | $208.18M | $207.74M | $200.26M | $189.62M | $185.19M | $180.86M | $173.16M | $251.66M | $143.91M | $146.62M | $131.19M | $228.78M | $192.50M | $123.44M | $115.39M | $207.98M | $107.02M | $105.48M | $94.75M | $189.07M | $90.61M | $89.72M | $85.09M | $80.49M | $89.54M | $84.50M |
| High Forecast | $222.80M | $231.63M | $216.24M | $207.45M | $213.92M | $213.47M | $205.78M | $192.60M | $202.22M | $181.41M | $173.16M | $301.99M | $152.76M | $151.10M | $134.81M | $274.54M | $231.00M | $123.44M | $115.39M | $249.58M | $107.02M | $105.48M | $94.75M | $226.89M | $90.61M | $89.72M | $85.09M | $96.58M | $89.54M | $84.50M |
| Low Forecast | $211.71M | $220.09M | $205.47M | $197.12M | $203.27M | $202.84M | $195.53M | $186.64M | $173.68M | $180.30M | $173.16M | $201.33M | $134.65M | $140.41M | $128.10M | $183.02M | $154.00M | $123.44M | $115.39M | $166.39M | $107.02M | $105.48M | $94.75M | $151.26M | $90.61M | $89.72M | $85.09M | $64.39M | $89.54M | $84.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | - | 0.38% | 0.86% | 0.80% | 1.23% | 0.38% | 1.20% | 1.03% | 1.19% | 0.62% | 1.15% | 0.74% | 1.24% | 1.16% | 1.17% | 1.18% |
United Therapeutics's average Quarter SG&A projection for Dec 23 is $143.91M, based on 8 Wall Street analysts, with a range of $134.65M to $152.76M. The forecast indicates a 12.78% rise compared to UTHR last annual SG&A of $127.60M (Sep 23).
United Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 9 | 4 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.71 | - | $5.20 | $2.88 | $5.26 | $2.56 | $5.31 | $2.49 | $3.62 | $3.85 | $0.63 | $2.22 | $3.86 | $2.43 | $3.14 | $1.20 | $3.02 |
| Avg Forecast | $7.66 | $7.96 | $7.44 | $7.14 | $7.66 | $8.10 | $7.81 | $7.19 | $6.58 | $6.52 | $6.51 | $5.74 | $4.19 | $5.10 | $4.57 | $4.59 | $4.72 | $3.91 | $4.39 | $3.65 | $3.58 | $3.59 | $3.02 | $3.03 | $2.95 | $2.84 | $2.77 | $2.74 | $2.64 | $2.54 |
| High Forecast | $7.93 | $8.25 | $7.70 | $7.40 | $7.94 | $8.39 | $8.09 | $7.27 | $8.08 | $6.53 | $6.52 | $5.76 | $5.30 | $5.69 | $4.73 | $4.75 | $4.99 | $3.91 | $4.39 | $3.65 | $3.58 | $3.59 | $3.02 | $3.03 | $2.95 | $2.84 | $2.77 | $2.74 | $2.64 | $2.54 |
| Low Forecast | $7.42 | $7.72 | $7.21 | $6.92 | $7.43 | $7.86 | $7.57 | $7.10 | $5.23 | $6.52 | $6.50 | $5.72 | $3.17 | $4.03 | $4.43 | $4.45 | $4.47 | $3.91 | $4.39 | $3.65 | $3.58 | $3.59 | $3.02 | $3.03 | $2.95 | $2.84 | $2.77 | $2.74 | $2.64 | $2.54 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.12% | - | 1.13% | 0.61% | 1.35% | 0.58% | 1.46% | 0.70% | 1.01% | 1.27% | 0.21% | 0.75% | 1.36% | 0.88% | 1.15% | 0.45% | 1.19% |
According to 8 Wall Street analysts, United Therapeutics's projected average Quarter EPS for Dec 23 is $4.19, with a low estimate of $3.17 and a high estimate of $5.30. This represents a -26.67% decrease compared to UTHR previous annual EPS of $5.71 (Sep 23).
United Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $1.94 | $33.86 | 1645.36% | Buy |
| LRMR | Larimar Therapeutics | $3.71 | $17.00 | 358.22% | Buy |
| LEGN | Legend Biotech | $36.10 | $89.60 | 148.20% | Buy |
| APLS | Apellis Pharmaceuticals | $29.47 | $70.80 | 140.24% | Buy |
| RARE | Ultragenyx Pharmaceutical | $42.47 | $90.00 | 111.91% | Buy |
| MNKD | MannKind | $6.11 | $12.00 | 96.40% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.01 | $24.00 | 84.47% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $20.66 | $37.50 | 81.51% | Buy |
| PCVX | Vaxcyte | $88.67 | $148.80 | 67.81% | Buy |
| ASND | Ascendis Pharma | $127.55 | $211.14 | 65.54% | Buy |
| REPL | Replimune Group | $14.07 | $23.00 | 63.47% | Buy |
| BGNE | BeiGene | $184.71 | $267.33 | 44.73% | Buy |
| NUVL | Nuvalent | $85.52 | $114.80 | 34.24% | Buy |
| INCY | Incyte | $73.72 | $95.38 | 29.38% | Buy |
| UTHR | United Therapeutics | $372.75 | $458.00 | 22.87% | Buy |
| ALNY | Alnylam Pharmaceuticals | $273.99 | $320.50 | 16.98% | Buy |
| BPMC | Blueprint Medicines | $114.32 | $127.00 | 11.09% | Buy |
| AKRO | Akero Therapeutics | $54.00 | $50.00 | -7.41% | Buy |